Delivery Order SPE2DB24D1201-SPE2DB26FJADF
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $26,044.32 to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count units) on September 24, 2025. This delivery order, which is classified as a child contract under a larger indefinite delivery vehicle, is structured as a firm fixed price arrangement with no set-aside designation, indicating it was competitively awarded. The place of performance is listed as AmerisourceBergen's corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $15,489.84 to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count units) under a firm fixed-price contract. This competitively awarded, non-set-aside delivery order was executed on September 11, 2025, with an ultimate completion date of September 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Jardiance 25 mg tablets (90-count) with a contract ceiling value of $31,642.05. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 15, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement supporting federal...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,325.30 to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count units) under a firm fixed price contract. This competitively awarded, non-set-aside order was issued on September 23, 2025, with an ultimate completion date of September 24, 2025. The pharmaceutical products will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,369.90 to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Jardiance 25 mg tablets (90-count units). This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of July 23, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Jardiance 25 mg tablets (90-count units) under a firm fixed price contract with a ceiling value of $16,930.73. This competitively awarded, non-set-aside delivery order is scheduled for completion by September 29, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major...
- The Defense Logistics Agency awarded a delivery order valued at $20,347.42 to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count) on June 3, 2025, with an ultimate completion date of June 4, 2025. This firm fixed-price, non-set-aside contract was awarded competitively and represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The performance location is AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,446.65 delivery order on August 4, 2025, for the supply of Jardiance 25 mg tablets (90-count). This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by August 5, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a continuation of AmerisourceBergen's substantial pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Jardiance 25 mg tablets (90-count units) with a ceiling value of $81,786.40. This competitively awarded, firm fixed-price delivery order is set to be completed by September 9, 2025, and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a $47,507.24 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count units) to be delivered by September 10, 2025. This non-set-aside competitive award leverages AmerisourceBergen's position as a critical pharmaceutical distributor supporting federal medical procurement needs. The contract was awarded on September 9, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania...
- SPE2DB24D1201Indefinite Delivery Contract
- SPE2DB24D1201-SPE2DB26FJADFDelivery Order
The Defense Logistics Agency (DLA) awarded a $42,982.24 firm fixed price delivery order to AmerisourceBergen Drug Corp on October 15, 2025, for the supply of Jardiance 25 mg tablets (90-count units). The contract, which is a non-set-aside competitive award, will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of October 16, 2025. This delivery order represents a single transaction within AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. This award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies an extensive portfolio of medications and medical supplies to support military and veteran healthcare systems, including the Defense Health Agency and U.S. Coast Guard. Jardiance, a diabetes medication, falls within the company's comprehensive therapeutic product range delivered through this global pharmaceutical support vehicle, which covers brand-name and generic drugs, vaccines, and specialized medical commodities across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $43.0k | 10/15/25 |